Rheumatoid Arthritis News

In this video, Jeffrey A. Sparks, MD, MMSc, associate physician at Brigham and Women's Hospital, explained findings from a study exploring metabolic issues and rheumatoid arthritis.

In this video, Dana DiRenzo, MD, MHS, instructor of medicine at Johns Hopkins, summarized “The Great Debate” at ACR 2020

Glucocorticoids should no longer be the “default” option for many patients with rheumatoid arthritis, according to authors of a new recommendation document presented at ACR Convergence 2020.

Patients with systemic autoimmune rheumatic diseases who contract COVID-19 may have a higher risk for end-organ failure than those without such diseases, according to a speaker at ACR Convergence 2020.

A model using machine learning was able to ascertain a simple selection rule to identify which patients with rheumatoid arthritis would benefit most from sarilumab, according to a speaker at the 2020 ACR Convergence Annual Meeting.

A long-term safety study of baricitinib for rheumatoid arthritis, with more than 13,000 patient-years of exposure, found no increase in safety issues for up to 8.4 years, according to a speaker at ACR Convergence.

Anifrolumab is superior to placebo for improved BILAG-2004 and SLEDAI-2K domain scores, as well as in mucocutaneous and musculoskeletal domains, among patients with systemic lupus erythematosus, according to a speaker at ACR Convergence.

Treatment with hydroxychloroquine does not impact corrected QT length among patients with rheumatoid arthritis or systemic lupus erythematosus, even after adjusting for confounders, according to a speaker at ACR Convergence.

The ACR’s annual Great Debate featured spirited arguments made for and against the use of janus kinase inhibitors before biologic therapy in the setting of methotrexate failure in rheumatoid arthritis.

Tuberculosis screening and clinical surveillance are needed for patients prescribed methotrexate — especially alongside corticosteroids or other immunosuppressants — in tuberculosis-endemic areas, according to a speaker at ACR Convergence.